2 leading ASX healthcare shares to buy and hold beyond 2030

Here we look at 2 leading ASX healthcare companies to buy and hold beyond 2030: CSL Limited (ASX: CSL) and ResMed Inc. (ASX: RMD).

a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The healthcare sector has been one of the top-performing sectors on the ASX in recent years with strong share price gains from a number of healthcare companies.

In my opinion, healthcare will continue to be one of the top-performing ASX sectors over the next decade, along with the tech sector, as the demand for healthcare services and products continues to increase, both locally and internationally.

Here we examine 2 leading S&P/ASX 200 Index (ASX: XJO) healthcare shares: CSL Limited (ASX: CSL) and ResMed Inc (ASX: RMD). Both companies have evolved over the last 5 to 10 years to become leading international companies in their respective healthcare fields, with strong revenue and profit growth.

I believe that this strong growth will continue well into the next decade, which is likely to translate into continued strong share price growth.

Other specialist ASX healthcare shares which I believe have strong growth potential include Cochlear Limited (ASX: COH) and Nanosonics Ltd (ASX: NAN).

CSL Limited

CSL has developed into a highly successful global business through innovative research treatments that are protected by product patents, combined with the utilisation of a highly efficient global production and distribution network that generates strong cash returns. These returns are then cleverly reinvested back into the company to develop further innovative products and make targeted acquisitions.

In the 12 months to 30 June 2019, CSL invested over US$800 million into research and development across its businesses, which amounts to around 10% of its total operating revenue.

CSL produces blood medicines and plasma products that could potentially play a vital role in the production of products to help in the coronavirus fight. It does have a major division within its company that produces vaccines, which it has called upon in the past in previous health crises such as the swine flu.

ResMed Inc

ResMed is another amazing Aussie success story, growing from a backyard Australian operation 30 years ago to now become a major US-based global company employing more than 7,500 people worldwide.

The company is a leading designer and manufacturer of healthcare devices and cloud-based software solutions, targeting sleep apnea and other respiratory conditions. Its global scale and breadth now provide it with a distinct advantage over its competitors.

This specialist healthcare product provider is currently a leading provider of cloud-based software solutions for out of hospital care and is seeing particularly strong growth from its software-as-a-service (SaaS) segment, which now constitutes around 12% of its total revenue. This percentage is likely to grow significantly over the next 5 years.

I believe that the strong demand for ResMed's products is likely to persist over the next decade. It is estimated that over 20% of US adults are unaware that they are suffering from sleep apnea, providing ResMed with a large potential untapped revenue stream.

Phil Harpur owns shares of Cochlear Ltd., CSL Ltd., Nanosonics Limited, and ResMed Inc. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. and CSL Ltd. The Motley Fool Australia owns shares of and has recommended Nanosonics Limited. The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »